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Abstract
Background: Pyrexia is a physiological response through which the immune system responds to infectious processes.
Hyperpyrexia is known to be neurodegenerative leading to brain damage. Some of the neurotoxic effects of hyperpyrexia
on the brain include seizures, decreased cognitive speed, mental status changes, coma, and even death. In the
clinical management of hyperpyrexia, the goal is to treat the underlying cause of elevated temperature and prevent
end organ damage.
Case presentation: This case illustrates a 39-year-old white American man referred from another medical facility
where he had undergone an upper gastrointestinal tract diagnostic procedure which became complicated by blood
aspiration and respiratory distress. During hospitalization, he developed a core body temperature of 41.6 °C (106.9 °F)
leading to cognitive decline and coma with a Glasgow Coma Score of 3. Levetiracetam and amantadine were utilized
effectively for preserving and restoring neurocognitive function. Prior studies have shown that glutamate levels can
increase during an infectious process. Glutamate is an excitatory neurotransmitter that is utilized by the organum
vasculosum laminae terminalis through the neuronal excitatory system and causes an increase in body temperature
which can lead to hyperpyrexia. Similar to neurogenic fevers, hyperpyrexia can lead to neurological decline and
irreversible cognitive dysfunction. Inhibition of the glutamate aids a decrease in excitatory states, and improves the
brain’s regulatory mechanism, including temperature control. To further improve cognitive function, dopamine levels
were increased with a dopamine agonist.
Conclusions: We propose that a combination of levetiracetam and amantadine may provide neuroprotective and
neurorestorative properties when administered during a period of hyperpyrexia accompanied by any form of mental
status changes, particularly if there is a decline in Glasgow Coma Score.
Keywords: Hyperpyrexia, Levetiracetam, Glutamate, Organum vasculosum laminae terminalis, Neuroprotection,
Amantadine, Glasgow Coma Score
Background
Fever is a natural regulatory protective mechanism through
which the human body counteracts physiological insults.
Causes of fever include infections, traumatic brain in-
jury, thalamic injury, dehydration, tissue destruction,
and thromboembolism [1, 2]. Conversely, hyperpyrexia
or body temperature greater than or equal to 41.5 °C
(106.7 °F) may lead to pathological complications including
detrimental mental status changes, neuronal brain injury,
cognitive decline, coma, and even death [2]. Causes of hy-
perpyrexia include neuroleptic malignant syndrome, heat
stroke, amphetamine overdose, serotonin syndrome, infec-
tions, and sepsis [2]. In a study conducted by Minamisawa
et al. [3], it was shown that hyperpyrexia induced panne-
crosis as well as damage to the neocortex, caudoputamen,
and substantia nigra pars reticulate, which are responsible
for dopamine activity. These areas of the brain are involved
in conscious reasoning, spatial orientation, sensation to all
modalities, movement regulation, and learning [3]. Regula-
tion of neuronal excitability occurs in the brain via balan-
cing of gamma-aminobutyric acid (GABA) and glutamate
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decarboxylase [4, 5]. Glutamate is a major excitatory neuro-
transmitter in the brain and serves as a precursor for the
synthesis of GABA, which can be inversely metabolized
back to glutamate via the tricarboxylic acid (TCA) cycle [6].
Dysfunction of neuronal activities in hypoxia, however,
causes poor regulation of TCA cycle causing uncontrolled
release of glutamate which becomes toxic to neurons and
thus inducing further neuronal necrosis in the brain [7].
Hyperpyrexia of infectious origin is discussed in this
case in combination with the pharmacological interven-
tions utilized following a severe mental status decline
leading to a comatose state. A combination of levetirace-
tam and amantadine were successfully utilized. Here, we
demonstrate the beneficial effect of neuroprotective agents
in fever regulation via the organum vasculosum laminae
terminalis (OVLT) and its function in fever regulation in a
patient with brain injury resulting from hyperpyrexia. The
OVLT glutamate spike has been studied in animals show-
ing a rise in glutamate levels prior to measurable increase
in body temperature [8]. This suggests a link between
hyperpyrexia and OVLT involvement in temperature
regulation via glutamate release [9]. While levetiracetam is
a known antiepileptic agent, its impact on regulating the
integrity of the blood–brain barrier function following
hyperpyrexia in a comatose state has not been well doc-
umented in humans [10]. Levetiracetam is documented
with a known mechanism of action in neuronal glutamate
regulation in seizure disorder via inhibition of presynaptic
calcium channels [11]. Following the assessment and review
of this case, we suggest that in patients with hyperpyrexia
and cognitive decline, a combination of amantadine and
levetiracetam could be beneficial for preserving neuronal
survival and restoring cognitive function.
Case presentation
A 39-year-old white American man with a past medical
history of hypertension, hyperlipidemia, and major depres-
sive disorder presented to our facility after being trans-
ferred from another facility following an attempted suicide.
He presented to our intensive care unit; he was intubated
due to respiratory distress and hypoxic-anoxic brain injury,
secondary to complications of sharp foreign object inges-
tion as a means of suicide attempt. According to collateral
information retrieved from the sending facility, he was seen
aspirating blood while undergoing esophagogastroduode-
noscopy (EGD) thus requiring emergency intubation. On
admission to our facility, an abdominal X-ray showed no
evidence of foreign object ingestion. Another EGD was
performed at our facility to investigate upper gastric
bleeding which revealed a 2 cm ulcer at the base of his
esophagus, which was cauterized resulting in control of
the hemorrhage. An abdominal axial computed tomog-
raphy (CT) scan performed on hospital day 18 showed
evidence of a foreign object in his descending colon which
was later expulsed via bowel movement on day 20. Per
transfer records received at our facility, medications in-
cluded amlodipine 5 mg orally daily, simvastatin 10 mg
orally daily, gemfibrozil 600 mg orally twice a day, and
niacin 500 mg daily. According to the history obtained
from members of his family, there were no reported
medication allergies and no past non-prescribed sub-
stance use history.
Within hours of admission to our intensive care unit,
his mental status progressively declined due to hypoxic-
anoxic brain injury reaching a Glasgow Coma Score (GCS)
of 6. On physical examination there was no eye opening re-
sponse, no verbal response, and he only merely withdrew
from painful stimuli. There was neither decorticate nor
decerebrate posturing at the time of examination. Lung
auscultation revealed decreased breath sounds in bilateral
lung bases. His abdomen was distended, obese, with
decreased bowel sounds in all four quadrants and tym-
panic to percussion. His white blood cell (WBC) count
was elevated at 14.9 (103/uL), with 83.6 % neutrophil
predominance. A chest X-ray showed bilateral pleural
effusion. A sputum culture was positive for Klebsiella
pneumonia. His clinical picture was consistent with as-
piration pneumonitis with severe hypoxia which later
decompensated to ventilator-associated pneumonia with
methicillin-resistant Staphylococcus aureus (MRSA) pneu-
monia (as seen on sputum culture), which thus made him
ventilator dependent due to decreased respiratory drive.
His treatment was a combination of levofloxacin 750 mg
administered intravenously daily, piperacillin/tazobactam
3.375 mg every 6 hours, and vancomycin 1 gram daily. On
day 8, a maximum core temperature (Tmax) of 39.6 °C
(103.3 °F) was recorded rectally. He had no motor
response to painful stimuli, no eye opening, nor verbal re-
sponse despite being off all sedating agents. His blood cul-
ture at this time was positive for Candida albicans and, as
a result, micafungin 100 mg administered intravenously
daily was initiated. While on this regimen, on day 9, a
temperature of 41.6 °C (106.9 °F) was recorded with a
GCS of 3. Acetaminophen 650 mg was administered rec-
tally; cooling blankets and multiple ice packs were applied
to his groin, axillae, and neck regions resulting in a de-
crease in his body temperature to 37.8 °C (100.1 °F) within
8 hours of intervention. He continued to have fever on a
daily basis with no improvement in cognitive functioning
as he remained comatose. On hospital day 11, he had
become flaccid and was considered to be in a vegetative
state as evidenced by an electroencephalogram (EEG)
study, which showed diffuse slowing consistent with en-
cephalopathy with very poor prognosis. His WBC count
increased to 27.9 (103/uL) and he remained in a state of
septicemia. Due to multiple failed attempts to wean him
off the ventilator, a tracheostomy was performed on day
14 and a percutaneous endoscopic gastrostomy (PEG)
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tube was placed on day 17. Given his neurological de-
cline, a lumbar puncture was considered for cerebro-
spinal fluid (CSF) analysis. However, he was already on
broad spectrum antibiotics, therefore, the benefits from
CSF analysis would have been undermined by antibiotic
coverage.
After concerted deliberations over the trial of leveti-
racetam as a neuroprotective and antiepileptic agent, the
decision was made on day 29 to administer 500 mg of
the medication via a PEG tube at bedtime. Within
48 hours of administration, he was awake and alert but
remained disoriented to person, place, and time. His
GCS improved from 3 to 14 and he was able to respond
to painful stimuli from his lower extremities up to his
knees. Amantadine 50 mg/ml via a PEG tube every
morning was started for neurocognitive stimulation as
he was noted to have decreased cognitive speed measured
grossly during conversation evidenced by increased latency
of response when questioned. On hospital day 38 (9 days
after levetiracetam 500 mg initiation), he was able to com-
municate verbally, although with difficulties with phonation
even with a Passy-Muir valve. There was orientation to per-
son and place but not to time. His body temperature was
37.3 °C (99.1 °F) without antipyretic agents, while his WBC
remained elevated at 20.9 (103/uL) showing persistence of
infection.
The finding of a neurological examination was consistent
with critical illness polyneuropathy, as he had no motor
function below the clavicle after surviving the profound
neurological impairment induced by hyperpyrexia. His pain
sensation remained intact, he responded to sharp and dull
touch sensations, and he responded to vibrations. He was
noted to have decreased cognitive speed; therefore, he re-
quired neurocognitive stimulation. Amantadine was initi-
ated on day 34, resulting in improved cognitive functioning
with noted increased cognitive speed during conversation.
Amantadine was increased to 100 mg/ml via a PEG tube
for enhancement of neuroprotection on day 41.
He was weaned off a ventilator, then transferred to our
medical floor and eventually discharged. Extensive re-
habilitation was recommended for neuromusculoskeletal
strengthening in all his extremities. A CT scan showed dif-
fuse brain atrophy disproportionate to his chronological
age; thus consistent with hypoxic ischemic brain injury.
Following cognitive recovery, he was awake, alert,
and oriented to time, place, person, and situation. He
remained with a motor strength of 0/5 bilaterally in
upper and lower extremities proximally and distally,
secondary to critical illness polyneuropathy; however,
he had intact temperature and pain sensation to all mo-
dalities in the upper and lower extremities, chest, abdo-
men, and face. He was seen on follow-up evaluation
6 months following initial encounter and he remained
cognitively intact.
Discussion
Body temperatures can be classified into different stages:
hypothermia <35 °C (<95 °F), normal 36.5 to 37.5 °C
(97.7 to 99.5 °F), fever 37.5 to 38.3 °C (99.5 to 100.9 °F),
and hyperpyrexia 38.0 to 41.5 °C (100.4 to 106.7 °F) [2].
Of interest, neuronal damage may occur at the range of
hyperthermia [12]. Significant in this case is an appre-
ciable Tmax of 41.6 °C (106.9 °F) followed by further
neurocognitive decline from GCS 6 to GCS 3 within
hours of increased core body temperature leading to
coma and a persistent vegetative state, which posed a
very poor recovery prognosis. In the event of hyperpy-
rexia, endoplasmic reticular stress occurs due to denaturing
of the inherent polypeptide chains, nuclei carrying genetic
information, and mitochondria [12]. In burn injuries, there
is rapid destruction of polypeptides; however, in hyperpy-
rexia, as narrated in this case for instance, temperature
raises gradually causing gradual dysfunction in the neuronal
polypeptide chains [12]. One of the most evident indica-
tions of intracranial neuronal interference as noted in this
case is decline in mental status and coma, which was sup-
ported by an EEG finding consistent with encephalopathy.
The OVLT is a brain structure present in the antero-
ventral third ventricle, which is connected to the median
preoptic nucleus in the hypothalamus, which helps in
regulating temperature, thirst, and vasopressin secretion
[13]. The OVLT utilizes glutamate in creating neuronal
excitation and action potential required in initiating
temperature increase [8, 14]. Glutamate levels are known
to increase slightly prior to a rise in body temperature
during infectious processes [9]. Studies performed on
rabbits showed evidence of OVLT glutamate spikes when
staphylococcal enterotoxin A was injected [9]. In our
case, while there was physiologic fever response given
the presence of multiple infections, hyperpyrexia ensued
thus damaging neuronal functioning as evidenced by the
further decrease in GCS from 6 to 3 following a docu-
mented temperature of 41.6 °C (106.9 °F). Excess avail-
ability of glutamate in a brain with neuronal necrosis
causes temperature regulation impairment thus mimick-
ing a neurogenic fever which is difficult to regulate [14].
As observed in this case, following the noted rise in
core body temperature, there was a decline in cognitive
function predisposing our patient to further irreversible
cognitive dysfunction similar to what is seen in neurogenic
fever. Given that there were multiple sources of identified
infections, which were poorly manageable using antibi-
otics, it was necessary to protect cognitive function by
means of decreasing the amount of glutamate that was be-
ing produced in his brain. Werner et al. [15] documented
that glutamate’s excitotoxicity mediated by the α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/
kainate-type of glutamate receptors is known to cause
damage to the neurons and the oligodendrocytes in the
Sterkel et al. Journal of Medical Case Reports  (2017) 11:40 Page 3 of 6
central nervous system. In this case, a similar scenario is
proposed based on the finding of changes in mental status.
The choice of levetiracetam was made for the purpose of
decreasing the excitogenic effects of glutamate; it was
found to be effective within 48 hours of administration as
our patient became awake and alert following a prior co-
matose state for 21 days.
As an antiepileptic agent, levetiracetam functions by
binding to neuronal synaptic vesicle glycoprotein 2A
and inhibiting presynaptic calcium channels which leads to
decreased cell excitation [11]. Prolonged excitatory states
with glutamate release from brain neurons occur in anoxic-
hypoxic brain injury via unregulated release of neurotrans-
mitters from the vesicles where they are normally stored
[16]. In hyperpyrexia, the excitatory states with continuous
release of neurotransmitters further induce necrosis which
usually can be noticed on CT imaging within 14 days of ini-
tial injury [17, 18] (Fig. 1). As further necrosis occurs, more
glutamate is released from damaged neurons causing more
excitatory states in the brain causing further cognitive de-
cline and coma due to excitatory neuronal states. Excito-
genicity caused by the release of glutamate after any form
of brain injury occurs due to reactive oxygen stress, which
occasionally causes epileptogenic foci in patients [19, 20].
In this case, our patient had hypoxic ischemic brain injury
and brain atrophy as seen on CT imaging. Levetiracetam
inhibits glutamate transmission through presynaptic P/Q-
type calcium channels thus decreasing neuronal excitation
[21]. The inhibition of glutamate release in our patient’s
brain led to improvement and preservation in brain
function by decreasing excitatory states in his brain and
assisting in improved fever regulation. Hence, we
theorize that the inhibition of action potential via
utilization of levetiracetam halted the progression of
neuronal damage in this patient thus preserving cogni-
tive function despite a temperature of 41.6 °C (106.9 °F).
In the absence of pharmacological intervention with
levetiracetam, a comatose state would have continued
with persistent vegetative state given the excitatory
state caused by glutamate release from damaged neu-
rons; his comatose state would have become irrevers-
ible without intervention. As shown by his positive
response to the regimen with levetiracetam within
48 hours of treatment, there is evidence to support
that the treatment response in this patient was due to
our pharmacological intervention. Without the pre-
scribed regimental intervention, he had remained in a
vegetative state for 21 days. However, within 9 days of
treatment with levetiracetam, his cognitive function
improved to the point that he was out of a comatose
state and able to verbalize complaints (Fig. 2). Sepsis
remained despite the cognitive intervention; leukocytosis
persisted due to septic emboli from endocarditis requiring
aortic valve replacement which was not performed during
admission. He remained on antibiotic treatment even after
discharge from our hospital and remained with persistent
leukocytosis (Table 1).
The role of amantadine in this case was that of neurocog-
nitive stimulation via dopamine agonist effects. In addition,
amantadine has neuroprotective properties via inhibition of
glutamatergic N-methyl-D-aspartate (NMDA) receptor re-
ducing the release of proinflammatory factors from acti-
vated microglia and increasing the expression of glial cell
line-derived neurotrophic factor (GNDF) in astroglia.
Wakefulness, a function associated with dopamine, was
further improved with the use of amantadine in this
patient [22, 23].
Prior to treatment with amantadine, our patient was
noted to have increased latency of response to questions
following recovery from comatose state. Following initi-
ation of amantadine 50 mg/mL via PEG tube daily on day
34 and 100 mg/mL via PEG tube daily on day 41, there
was improvement in his cognitive speed as measured by
improvement in speed of response, ability to initiate con-
versations, and spontaneous report of complaints. His
GCS was 15 following the combined pharmacological
intervention with levetiracetam and amantadine.
Limitations
Our inability to obtain a magnetic resonance imaging
(MRI) of his brain due to unavailability at our facility
Fig. 1 Computed tomography scan of brain without contrast showing
brain atrophy disproportionately advanced for patient’s age. Arrows
pointing to areas of atrophy
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Fig. 2 a Changes in core temperature. b Glasgow Coma Score. c Immune response before and after levetiracetam administration. WBC white
blood cells
Table 1 Choice of antibiotics based on antibiotics sensitivity studies
Day WBC count (Range) Temperature maximum Antibiotic regimen based on culture and sensitivity studies Microorganism
1–7 11.9–18.6 37.1 °C (98.7 °F) Piperacillin-tazobactam 3.375 g intravenously
Q 8 hours. Vancomycin 1 g intravenously
Q 12 hours
K. pneumoniae – sputum
8–13 10.6–29.5 41.6 °C (106.9 °F) Levofloxacin 500 mg intravenously Q 48 hours.
Micafungin 100 mg intravenously Q daily
K. pneumoniae – sputum.
C. albicans – blood
14–22 9.1–22.1 38.9 °C (102 °F) Levofloxacin 500 mg intravenously Q 48 hours C. albicans – blood and sputum
23–30 12.1–20.9 39.7 °C (103.4 °F) Fluconazole 100 mg/50 ml, 100 mg Q 24 hours C. albicans – blood
31–41 13.9–29.7 36.7–39.4 °C (98–103 °F) Levofloxacin 500 mg intravenously Q 48 hours.
Piperacillin-tazobactam 3.375 g intravenously
Q 8 hours
P. aeruginosa – stool and wound
42–49 12.6–17.5 36.7–39.4 °C (98–103 °F) Daptomycin 500 mg intravenously Q 8 hours S. epidermidis – skin, stool, blood
50–57 7.2–17.5 36.8–39.4 °C (98.3–102.9 °F) Metronidazole 500 mg intravenously Q 8 hours.
Linezolid 600 mg/300 ml Q 12 hours
MRSA – sputum. C. difficile – stool
58–67 10.1–15.9 36.5–37.6 °C (97.7–99.7 °F) Levofloxacin 750 mg intravenously Q 24 hours.
Daptomycin 500 mg intravenously Q 8 hours
MRSA – sputum
68–78 7.3–18.2 36.5–39.0 °C (97.7–102.2 °F) Vancomycin 1 g intravenously Q 12 hours.
Imipenem 500 mg intravenously Q 8 hours
MRSA – Blood
C. albicans Candida albicans, C. difficile Clostridium difficile, K. pneumonia Klebsiella pneumoniae, MRSA methicillin-resistant Staphylococcus aureus, P. aeruginosa
Pseudomonas aeruginosa, Q every, S. epidermidis Staphylococcus epidermidis, WBC white blood cells
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limits our evaluation of the structures of his brain follow-
ing recovery from a coma. CSF analyses were not able to
be obtained because he was on broad spectrum antibiotics
and it was not deemed medically necessary at the time.
Conclusions
Physicians should be aware that the combination of
hyperpyrexia and cognitive changes including coma
cause poor recovery due to neuronal brain damage. The
utilization of levetiracetam and amantadine may provide
neuroprotective and neurorestorative effects following
hyperpyrexia with coexisting cognitive decline. Our case
depicts the successful use of both medications in restoring
cognitive function following hyperpyrexia with extensive
comatose state. Given the successful recovery achieved in
this case, we suggest that further research, such as ran-
domized controlled trials, need to be explored in similar
cases to harness the benefits of the conceptualization
depicted in this case report.
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